Lupin gets USFDA nod for generic version of Edecrin tablets to treat Edema in US

Lupin has received US Food and Drug Administration (USFDA) approval for Ethacrynic Acid tablets, a generic version of Bausch Health's Edecrin tablets, in 25 mg strength.

New Delhi: Drug maker Lupin on Monday said it has received approval from the US health regulator to market Ethacrynic Acid tablets, used to treat edema in various conditions, in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) to market its product, a generic version of Bausch Health's Edecrin tablets, in 25 mg strength, Lupin said in a statement.

Read Also: Lupin gets USFDA nod for a version of Emend Injection to prevent vomiting associated with chemotherapy

As per IQVIA MAT June 2019 data, Ethacrynic Acid tablets had annual sales of around USD 24 million (about Rs 170 crore) in the US.

Based in Mumbai, the company's key focus areas include pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis.

Read Also: Lupin, Boehringer Ingelheim sign USD 700 million deal for novel oncology drug